{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-008570","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.383279+00:00","generated_at":"2026-05-15T22:37:55.512192+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Akari shareholders approve warrant exercises and share issuances at special meeting","bullets":["Shareholders voted overwhelmingly to approve exercisability of Series G, Placement Agent, Pre-Funded, and Note Exchange warrants.","Proposals covered up to ~10M ADSs from Series G/Placement Agent warrants and ~19M ADSs from Pre-Funded/Note Exchange warrants.","All five resolutions passed with over 99% of votes cast in favor; abstentions negligible.","Meeting held March 2, 2026; matters related to capital raises and note exchanges from Dec 2025 and Jan 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-008570","json":"https://secwatch.observer/filing/0001493152-26-008570.json","markdown":"https://secwatch.observer/filing/0001493152-26-008570.md","text":"https://secwatch.observer/filing/0001493152-26-008570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226008570/0001493152-26-008570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226008570/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:37:55.512192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}